EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Long‐Term Recurrence‐Free Survival After Surgery and Adjuvant Furmonertinib in a Patient With EGFR ‐Mutated Pulmonary Sarcomatoid Carcinoma: A Case Report

Minlian Nong, Xiang Tan

Cancer Reports · 2026-11 · 9 (11)

DOI: 10.1002/cnr2.70729 ↗
AbstractBibliografische Angaben

Abstract

ABSTRACT Background Pulmonary sarcomatoid carcinoma (PSC) is an extremely rare subtype of non‐small cell lung cancer (NSCLC), which generally shows limited response to chemoradiotherapy and confers poor overall survival (OS). Recent progress in molecular targeted therapy has provided potential therapeutic strategies for this disease. Herein, we report a rare case of PSC harboring concurrent EGFR L858R and PIK3CA exon 10 mutations. The patient underwent radical surgical resection followed by adjuvant third‐generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR‐TKI) targeted therapy, and sustained long‐term disease‐free survival (DFS) was observed during clinical follow‐up. Although this case showed a favorable outcome, causality cannot be established from a single case report. Whether adjuvant furmonertinib contributed to the long‐term DFS remains uncertain and requires further investigation. Case A middle‐aged female presented with cough, expectoration, and hemoptysis. Percutaneous lung biopsy confirmed Stage IIIA pulmonary sarcomatoid carcinoma, and radical surgical resection was subsequently performed. Postoperative next‐generation sequencing identified concomitant EGFR L858R and PIK3CA exon 10 mutations. The patient received adjuvant furmonertinib as postoperative targeted therapy. No tumor recurrence was detected throughout follow‐up, with a documented DFS of 48 months. Conclusion Surgical resection remains the primary treatment for patients with early‐stage PSC, and postoperative molecular testing is critical to identify targetable mutations. This patient obtained durable DFS after radical resection combined with adjuvant third‐generation EGFR‐TKI targeted therapy. Additional large‐scale studies are needed to confirm the efficacy of adjuvant EGFR‐TKIs in PSC patients with dual EGFR/PIK3CA mutations.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →